Giuseppe
Emeritus
J Infect Dis. 2009 Aug 12. [Epub ahead of print]
Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture.
Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. - Center for Clinical Pharmacology Research, Monipol, Krakow, Poland; 2Global Clinical Research and Development, Novartis Vaccines and Diagnostics, Siena, Italy; 3Clinical Serology Department, Novartis Vaccines and Diagnostics, Marburg, Germany; 4Scientific Affairs, Novartis Vaccines and Diagnostics, Cambridge, Massachusetts.
Background.
Immunization remains the best prevention strategy for influenza, but production constraints for egg-based influenza vaccines have prompted the development of innovative cell culture manufacturing processes. Here, we describe a novel cell culture-derived influenza vaccine (CCIV) produced in Madin-Darby canine kidney cells.
Methods.
This phase 3, observer-blind, randomized, multicenter study in Poland compared the immunogenicity of a CCIV and a conventional egg-based vaccine. Participants, stratified by age (adults 18-60 years, [Formula: see text]; elderly persons 61 years, [Formula: see text]), received a single intramuscular vaccination. Immunogenicity was assessed 21 days later by hemagglutination inhibition assay. Reactogenicity was assessed using self-completed diary cards.
Results.
The immunogenicity of CCIV was noninferior to that of the conventional vaccine for all 3 vaccine strains in both age groups, regardless of underlying health status. Both vaccines fulfilled European Union registration criteria and were well tolerated, with similar incidences of solicited local and systemic reactions in both age groups; the only significant difference was an increased frequency of mild or moderate pain with CCIV than the conventional vaccine among adult (22% vs 17%; [Formula: see text]) and elderly (9% vs 5%; [Formula: see text]) vaccinees.
Conclusions.
CCIV was well tolerated and highly immunogenic in adults 18 years of age or older. Cell culture may offer greater flexibility of supply during periods of high demand for both seasonal and pandemic vaccines.
Trial registration. ClinicalTrials.gov identifier: NCT00492063 .
PMID: 19673651 [PubMed - as supplied by publisher]
-
-----
Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture.
Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. - Center for Clinical Pharmacology Research, Monipol, Krakow, Poland; 2Global Clinical Research and Development, Novartis Vaccines and Diagnostics, Siena, Italy; 3Clinical Serology Department, Novartis Vaccines and Diagnostics, Marburg, Germany; 4Scientific Affairs, Novartis Vaccines and Diagnostics, Cambridge, Massachusetts.
Background.
Immunization remains the best prevention strategy for influenza, but production constraints for egg-based influenza vaccines have prompted the development of innovative cell culture manufacturing processes. Here, we describe a novel cell culture-derived influenza vaccine (CCIV) produced in Madin-Darby canine kidney cells.
Methods.
This phase 3, observer-blind, randomized, multicenter study in Poland compared the immunogenicity of a CCIV and a conventional egg-based vaccine. Participants, stratified by age (adults 18-60 years, [Formula: see text]; elderly persons 61 years, [Formula: see text]), received a single intramuscular vaccination. Immunogenicity was assessed 21 days later by hemagglutination inhibition assay. Reactogenicity was assessed using self-completed diary cards.
Results.
The immunogenicity of CCIV was noninferior to that of the conventional vaccine for all 3 vaccine strains in both age groups, regardless of underlying health status. Both vaccines fulfilled European Union registration criteria and were well tolerated, with similar incidences of solicited local and systemic reactions in both age groups; the only significant difference was an increased frequency of mild or moderate pain with CCIV than the conventional vaccine among adult (22% vs 17%; [Formula: see text]) and elderly (9% vs 5%; [Formula: see text]) vaccinees.
Conclusions.
CCIV was well tolerated and highly immunogenic in adults 18 years of age or older. Cell culture may offer greater flexibility of supply during periods of high demand for both seasonal and pandemic vaccines.
Trial registration. ClinicalTrials.gov identifier: NCT00492063 .
PMID: 19673651 [PubMed - as supplied by publisher]
-
-----